AP1374A - Aerosolizable particles resistant to hygroscopic growth. - Google Patents

Aerosolizable particles resistant to hygroscopic growth. Download PDF

Info

Publication number: AP1374A
Authority: AP; ARIPO
Prior art keywords: particles; active agent; hygroscopic; growth inhibitor; hygroscopic growth
Prior art date: 1998-09-14

Application number

APAP/P/2001/002093A

Other languages

English (en)

Other versions

AP2001002093A0 (en

Inventor

Andrew Clark

Mei-Chang Kuo

Cecily Lalor

Barry John Aldous

Original Assignee

Inhale Therapeutic Syst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-14

Filing date

1999-09-13

Publication date

2005-02-28

1999-09-13 Application filed by Inhale Therapeutic Syst filed Critical Inhale Therapeutic Syst

2001-03-31 Publication of AP2001002093A0 publication Critical patent/AP2001002093A0/xx

2005-02-28 Application granted granted Critical

2005-02-28 Publication of AP1374A publication Critical patent/AP1374A/en

Links

239000002245 particle Substances 0.000 title claims description 171
239000000843 powder Substances 0.000 claims abstract description 165
239000013543 active substance Substances 0.000 claims abstract description 88
210000004072 lung Anatomy 0.000 claims abstract description 81
239000000203 mixture Substances 0.000 claims abstract description 66
238000001179 sorption measurement Methods 0.000 claims abstract description 30
238000000034 method Methods 0.000 claims abstract description 28
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 58
239000003966 growth inhibitor Substances 0.000 claims description 51
BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims description 35
208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims description 35
229940050526 hydroxyethylstarch Drugs 0.000 claims description 32
229920001612 Hydroxyethyl starch Polymers 0.000 claims description 31
239000003814 drug Substances 0.000 claims description 31
DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 claims description 30
102000004877 Insulin Human genes 0.000 claims description 29
108090001061 Insulin Proteins 0.000 claims description 29
239000003795 chemical substances by application Substances 0.000 claims description 29
229940125396 insulin Drugs 0.000 claims description 29
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
229920000858 Cyclodextrin Polymers 0.000 claims description 20
230000002401 inhibitory effect Effects 0.000 claims description 18
239000000443 aerosol Substances 0.000 claims description 17
229920002307 Dextran Polymers 0.000 claims description 13
229960002086 dextran Drugs 0.000 claims description 12
238000009826 distribution Methods 0.000 claims description 11
108090000623 proteins and genes Proteins 0.000 claims description 11
239000001116 FEMA 4028 Substances 0.000 claims description 10
229920002774 Maltodextrin Polymers 0.000 claims description 10
229960004853 betadex Drugs 0.000 claims description 10
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 10
102000004196 processed proteins & peptides Human genes 0.000 claims description 10
108090000765 processed proteins & peptides Proteins 0.000 claims description 10
102000004169 proteins and genes Human genes 0.000 claims description 10
229920001605 Dextranomer Polymers 0.000 claims description 9
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 9
235000011175 beta-cyclodextrine Nutrition 0.000 claims description 9
229960002864 dextranomer Drugs 0.000 claims description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
229920001184 polypeptide Polymers 0.000 claims description 8
238000001694 spray drying Methods 0.000 claims description 8
239000005913 Maltodextrin Substances 0.000 claims description 5
229940112141 dry powder inhaler Drugs 0.000 claims description 5
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
229940035034 maltodextrin Drugs 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
102000055006 Calcitonin Human genes 0.000 claims description 4
108060001064 Calcitonin Proteins 0.000 claims description 4
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
229960004015 calcitonin Drugs 0.000 claims description 4
229940097362 cyclodextrins Drugs 0.000 claims description 4
239000003112 inhibitor Substances 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
229940067631 phospholipid Drugs 0.000 claims description 3
150000003904 phospholipids Chemical class 0.000 claims description 3
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 3
238000012387 aerosolization Methods 0.000 claims description 2
229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 4
ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 claims 3
NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims 2
239000003230 hygroscopic agent Substances 0.000 claims 2
PVPBHKCSQBLDEW-ZQOBQRRWSA-N (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol 4-hydroxybutane-1-sulfonic acid Chemical compound OCCCCS(O)(=O)=O.OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O PVPBHKCSQBLDEW-ZQOBQRRWSA-N 0.000 claims 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
210000004894 snout Anatomy 0.000 claims 1
238000009472 formulation Methods 0.000 abstract description 45
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 31
229940079593 drug Drugs 0.000 description 22
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 20
229930195725 Mannitol Natural products 0.000 description 20
239000000594 mannitol Substances 0.000 description 20
235000010355 mannitol Nutrition 0.000 description 20
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 20
239000001509 sodium citrate Substances 0.000 description 20
239000000463 material Substances 0.000 description 17
-1 vaccines Substances 0.000 description 17
230000001965 increasing effect Effects 0.000 description 16
230000002685 pulmonary effect Effects 0.000 description 16
239000004471 Glycine Substances 0.000 description 14
239000000546 pharmaceutical excipient Substances 0.000 description 14
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 13
230000007613 environmental effect Effects 0.000 description 10
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
230000008021 deposition Effects 0.000 description 8
238000010348 incorporation Methods 0.000 description 8
239000000243 solution Substances 0.000 description 8
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 7
102000008100 Human Serum Albumin Human genes 0.000 description 7
108091006905 Human Serum Albumin Proteins 0.000 description 7
239000006185 dispersion Substances 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
239000000523 sample Substances 0.000 description 7
239000007787 solid Substances 0.000 description 7
239000007921 spray Substances 0.000 description 7
238000010521 absorption reaction Methods 0.000 description 6
229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 6
108010068072 salmon calcitonin Proteins 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000008103 glucose Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
230000002093 peripheral effect Effects 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
239000010432 diamond Substances 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
239000007789 gas Substances 0.000 description 4
238000002156 mixing Methods 0.000 description 4
210000002345 respiratory system Anatomy 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
230000001839 systemic circulation Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
101000588924 Anthopleura elegantissima Delta-actitoxin-Ael1a Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
102000003982 Parathyroid hormone Human genes 0.000 description 3
108090000445 Parathyroid hormone Proteins 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000012867 bioactive agent Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229960004106 citric acid Drugs 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000010304 firing Methods 0.000 description 3
238000002221 gravimetric sorption analysis Methods 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
239000000199 parathyroid hormone Substances 0.000 description 3
229960001319 parathyroid hormone Drugs 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
238000012545 processing Methods 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
ZVCVMOFMPFNDBB-UHFFFAOYSA-N 1-sulfonyl-4-(4-sulfonylbutoxy)butane Chemical compound O=S(=O)=CCCCOCCCC=S(=O)=O ZVCVMOFMPFNDBB-UHFFFAOYSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
102100033735 Bactericidal permeability-increasing protein Human genes 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
108700012941 GNRH1 Proteins 0.000 description 2
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
101000871785 Homo sapiens Bactericidal permeability-increasing protein Proteins 0.000 description 2
102000002265 Human Growth Hormone Human genes 0.000 description 2
108010000521 Human Growth Hormone Proteins 0.000 description 2
239000000854 Human Growth Hormone Substances 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
101710142969 Somatoliberin Proteins 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
229940039227 diagnostic agent Drugs 0.000 description 2
239000000032 diagnostic agent Substances 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
229940028334 follicle stimulating hormone Drugs 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
229940071648 metered dose inhaler Drugs 0.000 description 2
150000002772 monosaccharides Chemical class 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000007873 sieving Methods 0.000 description 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
239000004474 valine Substances 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
NEZDNQCXEZDCBI-WJOKGBTCSA-N (2-aminoethoxy)[(2r)-2,3-bis(tetradecanoyloxy)propoxy]phosphinic acid Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-WJOKGBTCSA-N 0.000 description 1
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
102000009660 Cholinergic Receptors Human genes 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102000014429 Insulin-like growth factor Human genes 0.000 description 1
108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
DNDWZFHLZVYOGF-KKUMJFAQSA-N Leu-Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O DNDWZFHLZVYOGF-KKUMJFAQSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
231100000002 MTT assay Toxicity 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
108010016076 Octreotide Proteins 0.000 description 1
240000007673 Origanum vulgare Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
108010078233 Thymalfasin Proteins 0.000 description 1
102400000800 Thymosin alpha-1 Human genes 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
MKFFGUZYVNDHIH-UHFFFAOYSA-N [2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]-propan-2-ylazanium;sulfate Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC(O)=CC(O)=C1.CC(C)NCC(O)C1=CC(O)=CC(O)=C1 MKFFGUZYVNDHIH-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000003741 agents affecting lipid metabolism Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
229940057282 albuterol sulfate Drugs 0.000 description 1
108010060162 alglucerase Proteins 0.000 description 1
229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
229940043377 alpha-cyclodextrin Drugs 0.000 description 1
238000013103 analytical ultracentrifugation Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000003388 anti-hormonal effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
239000002216 antistatic agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical class C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000012159 carrier gas Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940049197 cerezyme Drugs 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000005354 coacervation Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
229960003662 desonide Drugs 0.000 description 1
229940119744 dextran 40 Drugs 0.000 description 1
229940119743 dextran 70 Drugs 0.000 description 1
229940119742 dextran 75 Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
229940037395 electrolytes Drugs 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229960001903 ergotamine tartrate Drugs 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229960000676 flunisolide Drugs 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
229960002714 fluticasone Drugs 0.000 description 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
229940080345 gamma-cyclodextrin Drugs 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229940125697 hormonal agent Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000005554 hypnotics and sedatives Substances 0.000 description 1
229940005535 hypnotics and sedatives Drugs 0.000 description 1
108010039650 imiglucerase Proteins 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
229960001388 interferon-beta Drugs 0.000 description 1
239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
229940028885 interleukin-4 Drugs 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
229960001361 ipratropium bromide Drugs 0.000 description 1
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
229960005280 isotretinoin Drugs 0.000 description 1
238000010902 jet-milling Methods 0.000 description 1
108010049589 leucyl-leucyl-leucine Proteins 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229940066294 lung surfactant Drugs 0.000 description 1
239000003580 lung surfactant Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229940042006 metaproterenol sulfate Drugs 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
229960002700 octreotide Drugs 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
230000035515 penetration Effects 0.000 description 1
XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
229960004448 pentamidine Drugs 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000008103 phosphatidic acids Chemical class 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000003236 psychic effect Effects 0.000 description 1
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000009517 secondary packaging Methods 0.000 description 1
238000004513 sizing Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229960000999 sodium citrate dihydrate Drugs 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000003068 static effect Effects 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000004441 surface measurement Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
150000004044 tetrasaccharides Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
229960004231 thymalfasin Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940073585 tromethamine hydrochloride Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)

APAP/P/2001/002093A 1998-09-14 1999-09-13 Aerosolizable particles resistant to hygroscopic growth. AP1374A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10016398P	1998-09-14	1998-09-14
PCT/US1999/021109 WO2000015262A1 (en)	1998-09-14	1999-09-13	Dry powder active agent pulmonary delivery

Publications (2)

Publication Number	Publication Date
AP2001002093A0 AP2001002093A0 (en)	2001-03-31
AP1374A true AP1374A (en)	2005-02-28

Family

ID=22278404

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/2001/002093A AP1374A (en)	1998-09-14	1999-09-13	Aerosolizable particles resistant to hygroscopic growth.

Country Status (44)

Country	Link
EP (1)	EP1117442A1 (is)
JP (1)	JP2002524535A (is)
KR (1)	KR20010075063A (is)
CN (1)	CN1317977A (is)
AP (1)	AP1374A (is)
AR (1)	AR022090A1 (is)
AU (1)	AU753014B2 (is)
BG (1)	BG105430A (is)
BR (1)	BR9913722A (is)
CA (1)	CA2343920A1 (is)
CO (1)	CO5130023A1 (is)
CZ (1)	CZ2001829A3 (is)
DZ (1)	DZ2892A1 (is)
EA (1)	EA003476B1 (is)
EE (1)	EE200100151A (is)
GE (1)	GEP20043257B (is)
GT (1)	GT199900156A (is)
HK (1)	HK1042231A1 (is)
HN (1)	HN1999000159A (is)
HR (1)	HRP20010189A2 (is)
HU (1)	HUP0103837A3 (is)
ID (1)	ID28845A (is)
IL (2)	IL141562A0 (is)
IS (1)	IS5878A (is)
LT (1)	LT4897B (is)
LV (1)	LV12658B (is)
MA (1)	MA25590A1 (is)
MY (1)	MY129282A (is)
NO (1)	NO20011251L (is)
NZ (1)	NZ510168A (is)
OA (1)	OA11781A (is)
PA (1)	PA8481901A1 (is)
PE (1)	PE20001061A1 (is)
PL (1)	PL195574B1 (is)
SA (1)	SA99200718B1 (is)
SK (1)	SK3442001A3 (is)
TN (1)	TNSN99173A1 (is)
TR (1)	TR200101182T2 (is)
TW (1)	TWI226248B (is)
UA (1)	UA76085C2 (is)
UY (1)	UY25711A1 (is)
WO (1)	WO2000015262A1 (is)
YU (1)	YU24201A (is)
ZA (1)	ZA200101995B (is)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6956021B1 (en)	1998-08-25	2005-10-18	Advanced Inhalation Research, Inc.	Stable spray-dried protein formulations
HK1049621A1 (zh)	1999-06-09	2003-05-23	罗伯特‧E‧希弗斯	超临界流体辅助的喷雾和鼓泡乾燥
US6475468B2 (en) *	2001-02-15	2002-11-05	Aeropharm Technology Incorporated	Modulated release particles for aerosol delivery
CA2446904A1 (en) *	2001-05-24	2003-04-03	Alexza Pharmaceuticals, Inc.	Delivery of drug esters through an inhalation route
EG24184A (en) *	2001-06-15	2008-10-08	Otsuka Pharma Co Ltd	Dry powder inhalation system for transpulmonary
CA2465675C (en)	2001-11-20	2008-06-10	Advanced Inhalation Research, Inc.	Improved particulate compositions for pulmonary delivery
US7759506B2 (en)	2002-02-25	2010-07-20	Diffusion Pharmaceuticals Llc	Bipolar trans carotenoid salts and their uses
WO2003072734A2 (en)	2002-02-25	2003-09-04	Diffusion Pharmaceuticals Llc	Bipolar trans carotenoid salts and their uses
CA2491129A1 (en) *	2002-07-03	2004-01-15	Brigham And Women's Hospital, Inc.	Central airway administration for systemic delivery of therapeutics
JP2006513238A (ja) *	2002-12-19	2006-04-20	ファルマシア・コーポレーション	吸湿性薬物を含む非‐吸湿性製剤
DE10338403A1 (de) *	2003-08-18	2005-03-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0327723D0 (en) *	2003-09-15	2003-12-31	Vectura Ltd	Pharmaceutical compositions
US20070020299A1 (en)	2003-12-31	2007-01-25	Pipkin James D	Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
BRPI0510119A (pt)	2004-04-23	2007-09-25	Cydex Inc	formulação para dpi contendo sulfoaquil éter de ciclodextrina
UA95903C2 (ru) *	2005-02-24	2011-09-26	Дифьюжен Фармасьютикалз Ллк	Транс-каротиноиды, их синтез, лекарственная форма и применение
KR20070110418A (ko) *	2005-03-09	2007-11-16	오노 야꾸힝 고교 가부시키가이샤	입자 및 그 입자를 함유하는 제제
SI2952197T1 (sl)	2005-10-26	2017-09-29	Cydex Pharmaceuticals, Inc.	Sestavki sulfoalkil eter ciklodekstrina in metode priprave le-tega
US20100269819A1 (en) *	2006-08-14	2010-10-28	Sievers Robert E	Human Powered Dry Powder Inhaler and Dry Powder Inhaler Compositions
CN101541311B (zh) *	2006-10-25	2013-01-23	大日本住友制药株式会社	不易结块的颗粒制剂
EP1925295A1 (de) *	2006-11-22	2008-05-28	Boehringer Ingelheim Pharma GmbH & Co. KG	Stabile Pulverformulierung enthaltend ein Anticholinergikum
EP3483140A1 (en)	2007-04-13	2019-05-15	Diffusion Pharmaceuticals LLC	Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
US12370352B2 (en)	2007-06-28	2025-07-29	Cydex Pharmaceuticals, Inc.	Nasal and ophthalmic delivery of aqueous corticosteroid solutions
EA201070544A1 (ru)	2007-10-31	2010-12-30	Диффьюжн Фармасьютикалз Ллс	Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
ES2661215T3 (es) *	2009-05-20	2018-03-28	Aeras	Composiciones víricas; inmunógenas; secadas por pulverización; estables
KR101875843B1 (ko)	2009-06-22	2018-07-06	디퓨젼 파마슈티컬즈 엘엘씨	확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도
CN105287473A (zh)	2010-06-02	2016-02-03	扩散药品有限公司	包含双极性反式类胡萝卜素的组合物及其应用
SG11201406208QA (en)	2012-05-03	2014-11-27	Janssen Sciences Ireland Uc	Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
BR112015010601B1 (pt) *	2012-11-09	2022-07-19	Civitas Therapeutics, Inc.	Composição farmacêutica e uso da composição
US20180043585A9 (en) *	2013-09-20	2018-02-15	Virginia Commonwealth University	Delivery of particles using hygroscopic excipients
AU2015338717B2 (en)	2014-10-31	2018-12-20	Glaxosmithkline Intellectual Property Development Limited	Powder formulation
WO2017165667A1 (en)	2016-03-24	2017-09-28	Diffusion Pharmaceuticals Llc	Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
US20220378727A1 (en) *	2021-05-14	2022-12-01	The University Of Hong Kong	Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
EP4493276A4 (en) *	2022-03-18	2025-03-05	Pulmocures Ilac Egitim Danismanlik A.S.	DOSAGE FORMS OF ACTIVE AGENTS AGAINST VIRAL DISEASES IN DRY POWDER INHALATOR DEVICES FOR SYMPTOMS DUE TO COVID-19 AND OTHER VIRAL LUNG DISEASES

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3155573A (en) *	1958-05-06	1964-11-03	Benger Lab Ltd	Inhalant composition and method of making same
EP0611567A1 (en) *	1992-06-12	1994-08-24	Teijin Limited	Ultrafine powder for inhalation and production thereof
WO1996019197A1 (en) *	1994-12-22	1996-06-27	Astra Aktiebolag	Aerosol formulations of peptides and proteins
WO1998031346A1 (en) *	1997-01-16	1998-07-23	Massachusetts Institute Of Technology	Preparation of particles for inhalation
WO1999038493A1 (en) *	1998-01-30	1999-08-05	Rtp Pharma Inc.	Microparticle inhalation formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5874064A (en)	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery

1999
- 1999-09-09 MA MA25762A patent/MA25590A1/fr unknown
- 1999-09-13 CN CN99810871A patent/CN1317977A/zh active Pending
- 1999-09-13 NZ NZ510168A patent/NZ510168A/en unknown
- 1999-09-13 SK SK344-2001A patent/SK3442001A3/sk unknown
- 1999-09-13 DZ DZ990192A patent/DZ2892A1/xx active
- 1999-09-13 JP JP2000569846A patent/JP2002524535A/ja not_active Withdrawn
- 1999-09-13 EP EP99969035A patent/EP1117442A1/en not_active Withdrawn
- 1999-09-13 TW TW088115876A patent/TWI226248B/zh not_active IP Right Cessation
- 1999-09-13 YU YU24201A patent/YU24201A/sh unknown
- 1999-09-13 PL PL99346768A patent/PL195574B1/pl not_active IP Right Cessation
- 1999-09-13 GE GEAP19995857A patent/GEP20043257B/en unknown
- 1999-09-13 AP APAP/P/2001/002093A patent/AP1374A/en active
- 1999-09-13 CZ CZ2001829A patent/CZ2001829A3/cs unknown
- 1999-09-13 ID IDW20010582A patent/ID28845A/id unknown
- 1999-09-13 PE PE1999000925A patent/PE20001061A1/es not_active Application Discontinuation
- 1999-09-13 HU HU0103837A patent/HUP0103837A3/hu unknown
- 1999-09-13 BR BR9913722-4A patent/BR9913722A/pt not_active IP Right Cessation
- 1999-09-13 HN HN1999000159A patent/HN1999000159A/es unknown
- 1999-09-13 IL IL14156299A patent/IL141562A0/xx not_active IP Right Cessation
- 1999-09-13 KR KR1020017003208A patent/KR20010075063A/ko not_active Ceased
- 1999-09-13 UA UA2001031707A patent/UA76085C2/uk unknown
- 1999-09-13 HR HR20010189A patent/HRP20010189A2/hr not_active Application Discontinuation
- 1999-09-13 AU AU60397/99A patent/AU753014B2/en not_active Ceased
- 1999-09-13 MY MYPI99003947A patent/MY129282A/en unknown
- 1999-09-13 EA EA200100300A patent/EA003476B1/ru active IP Right Revival
- 1999-09-13 AR ARP990104587A patent/AR022090A1/es unknown
- 1999-09-13 TR TR2001/01182T patent/TR200101182T2/xx unknown
- 1999-09-13 WO PCT/US1999/021109 patent/WO2000015262A1/en not_active Ceased
- 1999-09-13 ZA ZA200101995A patent/ZA200101995B/en unknown
- 1999-09-13 HK HK02101738.3A patent/HK1042231A1/zh unknown
- 1999-09-13 OA OA1200100063A patent/OA11781A/en unknown
- 1999-09-13 EE EEP200100151A patent/EE200100151A/xx unknown
- 1999-09-13 CA CA002343920A patent/CA2343920A1/en not_active Abandoned
- 1999-09-14 UY UY25711A patent/UY25711A1/es not_active Application Discontinuation
- 1999-09-14 CO CO99058265A patent/CO5130023A1/es unknown
- 1999-09-14 PA PA19998481901A patent/PA8481901A1/es unknown
- 1999-09-14 TN TNTNSN99173A patent/TNSN99173A1/fr unknown
- 1999-09-14 GT GT199900156A patent/GT199900156A/es unknown
- 1999-10-31 SA SA99200718A patent/SA99200718B1/ar unknown
2001
- 2001-02-21 IL IL141562A patent/IL141562A/en unknown
- 2001-03-05 IS IS5878A patent/IS5878A/is unknown
- 2001-03-13 NO NO20011251A patent/NO20011251L/no not_active Application Discontinuation
- 2001-03-14 LT LT2001021A patent/LT4897B/lt not_active IP Right Cessation
- 2001-03-14 LV LV010041A patent/LV12658B/xx unknown
- 2001-04-10 BG BG105430A patent/BG105430A/xx unknown

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3155573A (en) *	1958-05-06	1964-11-03	Benger Lab Ltd	Inhalant composition and method of making same
EP0611567A1 (en) *	1992-06-12	1994-08-24	Teijin Limited	Ultrafine powder for inhalation and production thereof
WO1996019197A1 (en) *	1994-12-22	1996-06-27	Astra Aktiebolag	Aerosol formulations of peptides and proteins
WO1998031346A1 (en) *	1997-01-16	1998-07-23	Massachusetts Institute Of Technology	Preparation of particles for inhalation
WO1999038493A1 (en) *	1998-01-30	1999-08-05	Rtp Pharma Inc.	Microparticle inhalation formulations

Also Published As

Publication number	Publication date
JP2002524535A (ja)	2002-08-06
MA25590A1 (fr)	2002-12-31
WO2000015262A1 (en)	2000-03-23
YU24201A (sh)	2003-08-29
PE20001061A1 (es)	2000-10-08
MY129282A (en)	2007-03-30
IL141562A (en)	2007-07-24
CA2343920A1 (en)	2000-03-23
CN1317977A (zh)	2001-10-17
ID28845A (id)	2001-07-05
HRP20010189A2 (en)	2005-04-30
CZ2001829A3 (cs)	2001-09-12
CO5130023A1 (es)	2002-02-27
PL195574B1 (pl)	2007-10-31
LT4897B (lt)	2002-02-25
PA8481901A1 (es)	2002-04-25
LT2001021A (en)	2001-11-26
OA11781A (en)	2005-07-26
BG105430A (en)	2001-12-29
HUP0103837A2 (hu)	2002-05-29
HK1042231A1 (zh)	2002-08-09
NZ510168A (en)	2003-09-26
ZA200101995B (en)	2002-03-11
AU753014B2 (en)	2002-10-03
TNSN99173A1 (fr)	2005-11-10
EE200100151A (et)	2002-06-17
LV12658B (lv)	2001-09-20
LV12658A (lv)	2001-05-20
EP1117442A1 (en)	2001-07-25
UA76085C2 (en)	2006-07-17
GT199900156A (es)	2001-03-07
SA99200718B1 (ar)	2006-11-04
PL346768A1 (en)	2002-02-25
GEP20043257B (en)	2004-06-25
AP2001002093A0 (en)	2001-03-31
TWI226248B (en)	2005-01-11
DZ2892A1 (fr)	2003-12-15
UY25711A1 (es)	1999-11-17
NO20011251L (no)	2001-04-17
AR022090A1 (es)	2002-09-04
TR200101182T2 (tr)	2001-09-21
HUP0103837A3 (en)	2002-11-28
IL141562A0 (en)	2002-03-10
NO20011251D0 (no)	2001-03-13
IS5878A (is)	2001-03-05
EA003476B1 (ru)	2003-06-26
HN1999000159A (es)	1999-11-11
BR9913722A (pt)	2001-05-29
KR20010075063A (ko)	2001-08-09
EA200100300A1 (ru)	2001-10-22
AU6039799A (en)	2000-04-03
SK3442001A3 (en)	2001-11-06

Publication	Publication Date	Title
AU753014B2 (en)	2002-10-03	Dry powder active agent pulmonary delivery
USRE37053E1 (en)	2001-02-13	Particles incorporating surfactants for pulmonary drug delivery
US5855913A (en)	1999-01-05	Particles incorporating surfactants for pulmonary drug delivery
CA2336139C (en)	2008-10-14	Large porous particles emitted from an inhaler
US5985309A (en)	1999-11-16	Preparation of particles for inhalation
US6652837B1 (en)	2003-11-25	Preparation of novel particles for inhalation
CA2277801C (en)	2002-10-15	Preparation of particles for inhalation
US7625865B2 (en)	2009-12-01	Insulin highly respirable microparticles
ES2909080T3 (es)	2022-05-05	Formulación de DPI que contiene sulfoalquil éter ciclodextrina
SK7772001A3 (en)	2001-12-03	Particles of amino acid, process for their preparation, powder containing same, process for the preparation of such powder, an inhalator containing such powder, and their use
US20030113272A1 (en)	2003-06-19	Powders comprising anti-adherent materials for use in dry powder inhalers
PL209876B1 (pl)	2011-10-31	Sposób wytwarzania sproszkowanego preparatu do przyjmowania przez wdychanie, układ inhalowania proszkowego do przyjmowania przez wdychanie i zastosowanie liofilizowanej kompozycji do wytwarzania sproszkowanego preparatu do przyjmowania przez wdychanie
CN111202722A (zh)	2020-05-29	一种洛匹那韦吸入干粉药物组合物及其制备方法
Wang et al.	2009	Characterization of a new inhalable thymopentin formulation
Li et al.	2010	The use of sodium carboxymethylcellulose in the preparation of spray-dried proteins for pulmonary drug delivery
MXPA06014502A (es)	2007-03-12	Reduccion de retencion de polvo en superficies.
WO2025237925A1 (en)	2025-11-20	A dry powder composition comprising glp-1 antagonist
MXPA01002649A (en)	2001-12-04	Dry powder active agent pulmonary delivery
Batycky et al.	2002	The development of large porous particles for inhalation drug delivery
CA2403349C (en)	2008-01-29	Preparation of particles for inhalation
EP1273290A1 (en)	2003-01-08	Large porous particles emitted from an inhaler
EP1498115A1 (en)	2005-01-19	Preparation of particles for inhalation